Skip to Main Content

Paper Details

NKG2A is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple Negative Breast Cancer.
0
2023
CD8+, IFN, MHC-, MHC-I, MHC-I murine models, NK cell, NK cells, NK:T cell, NKG2A, PD-L1, T cell, TNBC, Triple Negative Breast Cancer, anti-, anti-NKG2A, cancer, human, murine, patient, patients, triple-negative breast cancer, tumor, tumors
Author NameAffiliation
Paula I Gonzalez-EricssonVanderbilt University Medical Center
Melinda E SandersVanderbilt University Medical Center
Claudine IsaacsGeorgetown University Medical Center
Justin M BalkoVanderbilt University
  • 1 - 4

Datasets

Release 1.2